Connor, Clark & Lunn Investment Management (CC&L)
LAB icon

Connor, Clark & Lunn Investment Management (CC&L)’s Standard BioTools LAB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Buy
+20,809
New +$19.7K ﹤0.01% 1619
2022
Q1 		– Sell
-249,944
Closed -$980K – 1129
2021
Q4 		$980K Buy
249,944
+5,828
+2% +$27.3K ﹤0.01% 682
2021
Q3 		$1.61M Buy
244,116
+233,251
+2,147% +$1.53M 0.01% 560
2021
Q2 		$67K Sell
10,865
-138,650
-93% -$741K ﹤0.01% 950
2021
Q1 		$676K Sell
149,515
-143,742
-49% -$790K ﹤0.01% 754
2020
Q4 		$1.76M Buy
293,257
+4,416
+2% +$29K 0.01% 529
2020
Q3 		$2.15M Buy
288,841
+166,717
+137% +$1.15M 0.01% 466
2020
Q2 		$490K Sell
122,124
-31,283
-20% -$109K ﹤0.01% 761
2020
Q1 		$390K Buy
+153,407
New +$504K ﹤0.01% 751
2019
Q3 		– Sell
-63,201
Closed -$779K – 1026
2019
Q2 		$779K Sell
63,201
-25,955
-29% -$331K 0.01% 623
2019
Q1 		$1.19M Buy
89,156
+1,224
+1% +$12.9K 0.01% 497
2018
Q4 		$758K Sell
87,932
-92,100
-51% -$717K 0.01% 608
2018
Q3 		$1.35M Sell
180,032
-2,063
-1% -$14.7K 0.01% 520
2018
Q2 		$1.08M Sell
182,095
-6,700
-4% -$38.2K 0.01% 597
2018
Q1 		$1.1M Buy
188,795
+43,950
+30% +$289K 0.01% 475
2017
Q4 		$853K Buy
144,845
+34,519
+31% +$189K 0.01% 539
2017
Q3 		$556K Buy
110,326
+37,201
+51% +$156K ﹤0.01% 629
2017
Q2 		$295K Buy
73,125
+52,625
+257% +$250K ﹤0.01% 684
2017
Q1 		$117K Sell
20,500
-1,600
-7% -$10.1K ﹤0.01% 841
2016
Q4 		$161K Sell
22,100
-35,775
-62% -$225K ﹤0.01% 811
2016
Q3 		$464K Buy
57,875
+11,100
+24% +$102K ﹤0.01% 593
2016
Q2 		$422K Sell
46,775
-2,375
-5% -$22.3K ﹤0.01% 613
2016
Q1 		$397K Sell
49,150
-300
-0.6% -$2.16K ﹤0.01% 603
2015
Q4 		$535K Buy
+49,450
New +$486K ﹤0.01% 531

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LAB Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Standard BioTools (LAB) in Q2 2026: 20,809 shares worth $17.1K. The stake represents ﹤0.01% of the portfolio and ranks #1619 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in LAB as recently as Q4 2021.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LAB in Q4 2015 and has held it in 24 quarters since. The position peaked at $2.15M in Q3 2020. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 20,809 shares of Standard BioTools worth $17.1K as of Q2 2026.
  • Standard BioTools was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1619 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Standard BioTools in Q4 2015 and has held it in 24 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Standard BioTools position peaked at $2.15M in Q3 2020.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.